Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir prophylaxis for CMV reactivation prevention in adults with graft-versus-host disease after allogeneic bone marrow transplant
MOH_2023-02-06_012336Phase 2Not yet recruiting
- Sponsor
- פרופ' משה ישורון
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by פרופ' משה ישורון. Primary endpoint: Not specified. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on MOH_2023-02-06_012336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-06_012336.